KRAS and cancer: In colorectal cancer (CRC) approximately 30% to 50% of tumors have KRAS mutations that occur early in the tumorigenesis pathway, so the detection of KRAS mutations is useful for early diagnosis, prognosis and evaluation of the therapeutic outcome in cancer treatment [22].